Background: Genital warts are caused by human papillomavirus (HPV); over 90% are due to
HPV types 6 and 11. We determined the percentage of persons who reported having been …

Background We conducted a large national cohort study to examine the risk of cancer
among men and women with genital warts (GW). Methods By use of the Danish National …

Objectives Since the introduction of Australia's human papillomavirus vaccination program,
the management rate of genital warts in sexual health clinics and private hospitals has …

Background The placebo arm of human papillomavirus (HPV) vaccine trials helps define the
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …

The licensure of a vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18
represents a major advance in the armamentarium for preventing cervical cancer, genital …

Objectives To assess the prevalence and correlates of self-reported genital warts (GWs)
among women and men aged 18–45 years in the Baltic countries. Methods In 2011–2013 …

The objective of this study was to estimate the lifetime age-specific cumulative incidence of
self-reported genital warts diagnosis in Slovenia and to explore the association with …

Background We assessed the effectiveness of the quadrivalent human papillomavirus
vaccine (qHPV) vaccination program in Manitoba, Canada, in reducing incident anogenital …

Objective Genital warts are the most common sexually transmitted disease and have a
detrimental impact on quality of life. Genital warts could be prevented by prophylactic HPV …

Background: A vaccine has recently been licensed in many countries that protects against
the human papillomavirus types 6, 11, 16, and 18. Types 6 and 11 account for approximately …